Lin Jie, Xue Binbin, Li Xiang, Xia Junhui
a Department of Neurology , The First Affiliated Hospital of Wenzhou Medical University , Wenzhou , Zhejiang , China.
b Department of Anesthesiology , The First Affiliated Hospital of Wenzhou Medical University , Zhejiang , Wenzhou , China.
Int J Neurosci. 2017 Aug;127(8):735-744. doi: 10.1080/00207454.2016.1242587. Epub 2016 Oct 14.
Monoclonal-antibody has been used for patients with autoimmune disorders for several years, and efficacy and safety were appreciated for these patients. Neuromyelitis optica specturm disorder (NMOSD) has been defined as an autoimmune demyelination disorder of the central nervous system (CNS) with a course of relapse-remission. Treatment of prevention is important for patients with NMOSD because of the increased disability after several attacks. Multiple factors were involved in the pathogenesis of NMOSD. Currently, targeting specific factor was favored in the research into the treatment for NMOSD. Previous studies reported the efficacy and tolerance in NMOSD for drugs such as rituximab, tocilizumab, and eculizumab. The aim of this article is to review the current monoclonal therapies for NMOSD patients, and also future alternative options.
单克隆抗体已用于自身免疫性疾病患者数年，这些患者对其疗效和安全性表示认可。视神经脊髓炎谱系障碍（NMOSD）已被定义为一种中枢神经系统（CNS）的自身免疫性脱髓鞘疾病，病程呈复发-缓解型。由于多次发作后残疾程度增加，预防治疗对NMOSD患者很重要。NMOSD的发病机制涉及多个因素。目前，在NMOSD治疗研究中倾向于靶向特定因子。先前的研究报道了利妥昔单抗、托珠单抗和依库珠单抗等药物在NMOSD中的疗效和耐受性。本文的目的是综述目前针对NMOSD患者的单克隆疗法以及未来的替代选择。
